Table 1.
Characteristics of included studies
Study (ref) | Country | Target population | Baseline Calcium intake as Low (< 900 mg/day), Adequate (>900g/day), Not specified) |
Dose of Supplementation (Cumulative dose) |
Duration of supplementation | GRADE quality |
---|---|---|---|---|---|---|
Belizan et al 1991[37] | Argentina | Nulliparous pregnant women, < 20 weeks gestation. No comorbid | Low | 2 g/day | < 20 weeks of pregnancy till delivery | High |
Kumar et al 2009 [38] | India | Primigravida women with gestational age between 12-25 weeks | Low | 2 g/day | 12-25 weeks of pregnancy till delivery | High |
L-Jaramillo et al. 1989[41] | Ecuador | Nulliparous pregnant women, < 24 weeks of gestation. No comorbid |
Low | 2 g/day | 23 weeks of pregnancy till delivery | Moderate |
L-Jaramillo et al. 1990[40] | Ecuador | Nulliparous pregnant women in 28-30 weeks of gestation with positive roll over test | Low | 2 g/day | 28-30 weeks of pregnancy till delivery | Moderate |
L-Jaramillo et al.1997[39] | Ecuador | Teenage (< 17.5 years) Nulliparous pregnant women < 20 weeks gestation. No comorbids or addiction | Low | 2 g/day | 20 weeks of pregnancy till delivery | High |
Niromanesh et al. 2001[42] | Turkey | 28-32 weeks pregnant women with positive roll over test and with at least one risk factor for pre-eclampsia. No chronic medical condition | Not specified | 2 g/day | 28-32 weeks of pregnancy till delivery | High |
Purwar et al. 1996[43] | India | Nulliparous pregnant women < 20 weeks of gestation. No cormorbid | Low | 2 g/day | 20 weeks of pregnancy till delivery | High |
Villar et al. 2006 [44] | Multicenter trial (Argentina, Egypt, India, Peru, South Africa and Vietnam) | Primiparous women < 20 weeks of gestation. No comorbids | Low | 1.5 g/day | From enrollment till delivery | High |
Taherian et al. 2002[46] | Iran | Nulliparous pregnant women < 20 weeks of gestation. No comrbids | Low | 500 mg/day | From enrollment till delivery | Moderate |
Wanchu et al. 2001[45] | India | Nulliparous pregnant women < 20 weeks of gestation. No known comorbids | Low | 2 g/day | From enrollment till delivery | Moderate |